How to use biological agents to treat straight spinal disease?
Biological agents are currently one of the more effective drugs for the treatment of direct spinal disease, and the following are the methods of their use and the relevant points: First, pre-use assessment. Disease activity assessment requires an assessment of the extent of disease activity of patients with direct spinal disease before using biological agents. The Bath Active Activity Index (BASDAI) is commonly used to judge disease activity by assessing six aspects of the patient ‘ s fatigue, spinal pain, external cortex pain, limited stress, morning stagnating time and extent over the past week. The use of biological agents is considered only when the disease is active and traditional treatment drugs (e.g., non-paralytics) are ineffective. TB screening is necessary before use because biological agents may increase the risk of nodule infection. Screening projects include a nodule fungus test (PPD test) or a gamma-disruptive release test (IGRA), combined with a chest X-line or CT examination to remove latent tuberculosis infections. In the case of latent nodules, anti-tuberculosis treatment is required before biological agents can be used. The screening of other infections also requires the examination of whether the patient is infected with hepatitis B, C, HIV, etc. For persons carrying hepatitis B virus, the use of biological agents may require simultaneous antiviral treatment to prevent the activation of hepatitis B virus.
ii. Type of drug and cause of tumour malformation – α (TNF – α) constrictor (Etanercept): This is a combination of protein, usually administered by subcutaneous injection. The recommended dose for adults is 25 mg per time, 2 times a week, 3-4 days apart. Injecting parts generally choose the thigh, abdominal or upper arm and need to rotate to reduce local skin reactions. For example, this time in the thigh, the next time you can choose the abdominal. Infliximab: It’s a human-rat-embedded single clone antibodies. It’s the way it’s given meds. The first dose is 3 – 5 mg/kg, one each in 0, 2 and 6 weeks and one every 6 – 8 weeks thereafter, and the specific dose and interval may need to be adjusted to the patient ‘ s condition and response. During the loss of the bets, the patient needs to be closely monitored for adverse reactions such as allergies. Adalimumab: It is a single cloned antibodies of all human origin that is injected under the skin. The recommended dose is 40 mg per second week. Patients or health-care personnel need to be trained before injection, to ensure that the correct method of injection is used and, after injection, to observe if there is a response, such as swelling, pain, etc. White cell media – 17A (IL – 17A) The Antigen Division, Secukinumab, is a monoclonic antibody for subcutaneous injection. The first dose was 150 mg, which was given during the 0th, 1st, 2, 3rd and 4th weeks respectively, followed by a monthly rate of 150 mg each. In the first few weeks after the introduction of the drug, some patients may experience mild infections, such as nasal inflammation, which requires close attention.
Monitoring of therapeutic effects during use requires periodic (generally every 3 – 6 months) assessment of patient symptoms and signs improvement during treatment with biological agents. For example, the efficacy of the drug is judged by measuring the extent of the spinal column activity (e.g., the Schober test) and laboratory indicators (e.g., blood sunk, C-reacting protein) by observing whether the spinal pain, rigidity of the patient has been reduced and the joint activity has improved. If treatment does not work optimally, there may be a need to adjust drug doses or to replace biological agents. Safety monitoring pays close attention to the adverse effects of drugs. In addition to the risk of infection mentioned earlier, there is a risk of injecting, allergies, autoimmune diseases, etc. When TNF-α is used, some patients may experience new skin changes, such as silver crumbs and rashes. Patients who have adverse effects such as fever, rashes and respiratory difficulties during use should immediately seek medical treatment and consider suspending the use of biological agents. At the same time, laboratory examinations such as blood routines, liver and kidney functions are regularly conducted to monitor the potential effects of drugs on the body. The use of biological agents needs to be carried out under the strict guidance of a doctor, who will develop individualized treatments based on the patient ‘ s specific circumstances.
